Pharmacogenetics in chemotherapy of colorectal cancer

Best Practice and Research: Clinical Gastroenterology

Volumn 23, Issue 2, 2009, Pages 257-273

  Henriette Tanja, Lieke ^a   Guchelaar, Henk Jan ^a   Gelderblom, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

chemotherapy; colorectal cancer; germline polymorphisms; pharmacogenetics; survival; toxicity

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLITE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G; IRINOTECAN; OXALIPLATIN; PACLITAXEL; RITUXIMAB; THYMIDYLATE SYNTHASE; TRASTUZUMAB; VASCULOTROPIN; XRCC1 PROTEIN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COLORECTAL CARCINOMA; DNA REPAIR; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; ENHANCER REGION; GASTROINTESTINAL TOXICITY; GENETIC MARKER; HUMAN; NEUTROPENIA; PHARMACOGENOMICS; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; SOLID TUMOR; SYSTEMIC THERAPY; VARIABLE NUMBER OF TANDEM REPEAT;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC SCREENING; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 65349125304     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2009.02.011     Document Type: Article

References (109)

1. Punt C.J. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuxin in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol (2008) May 20 suppl, Abstr LBA4011
2. Swen J.J., Huizinga T.W., Gelderblom H., et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 4 (2007) e209
3. Lecomte T., Ferraz J.M., Zinzindohoue F., et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10 (2004) 5880-5888
4. Mandola M.V., Stoehlmacher J., Muller-Weeks S., et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63 (2003) 2898-2904
5. Kawakami K., Salonga D., Park J.M., et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7 (2001) 4096-4101
6. Pullarkat S.T., Stoehlmacher J., Ghaderi V., et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1 (2001) 65-70
7. Marsh S., McKay J.A., Cassidy J., and Mcleod H. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19 (2001) 383-386
8. Park D.J., Stoehlmacher J., Zhang W., et al. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 17 (2002) 46-49
9. Salgado J., Zabalegui N., Gil C., et al. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 17 (2007) 325-328
10. Schwab M., Zanger U.M., Marx C., et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26 (2008) 2131-2138
11. Hitre E., Budai B., Adleff V., et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 15 (2005) 723-730
12. Jakobsen A., Nielsen J.N., Gyldenkerne N., et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23 (2005) 1365-1369
13. Largillier R., Etienne-Grimaldi M.C., Formento J.L., et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 12 (2006) 5496-5502
14. Ruzzo A., Graziano F., Kawakami K., et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24 (2006) 1883-1891
15. Marcuello E., Altes A., Del R.E., et al. Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112 (2004) 733-737
16. Ulrich C.M., Bigler J., Velicer C.M., et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9 (2000) 1381-1385
17. Keam B., Im S.A., Han S.W., et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 8 (2008) 148
18. Lu J.W., Gao C.M., Wu J.Z., et al. Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet 51 (2006) 155-160
19. Dotor E., Cuatrecases M., Martinez-Iniesta M., et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24 (2006) 1603-1611
20. Sharma R., Hoskins J.M., Rivory L.P., et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 14 (2008) 817-825
21. Terrazzino S., Agostini M., Pucciarelli S., et al. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics 16 (2006) 817-824
22. Cohen V., Panet-Raymond V., Sabbaghian N., et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9 (2003) 1611-1615
23. Ruzzo A., Graziano F., Loupakis F., et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25 (2007) 1247-1254
24. Suh K.W., Kim J.H., Kim D.Y., et al. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?. Ann Surg Oncol 13 (2006) 1379-1385
25. Heggie G.D., Sommadossi J.P., Cross D.S., et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47 (1987) 2203-2206
26. Van Kuilenburg A.B., Muller E.W., Haasjes J., et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency. Clin Cancer Res 7 (2001) 1149-1153
27. Etienne M.C., Lagrange J.L., Dassonville O., et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12 (1994) 2248-2253
28. Van Kuilenburg A.B., Meinsma R., Zoetekouw L., et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14 + 1g > a mutation. Int J Cancer 101 (2002) 253-258
29. Hsiao H.H., Yang M.Y., Chang J.G., et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol 53 (2004) 445-451
30. Ridge S.A., Sludden J., Brown O., et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 46 (1998) 151-156
31. Raida M., Schwabe W., Hausler P., et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7 (2001) 2832-2839
32. Gupta E., Lestingi T.M., Mick R., et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54 (1994) 3723-3725
33. Iyer L., King C.D., Whitington P.F., et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101 (1998) 847-854
34. Sai K., Saeki M., Saito Y., et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75 (2004) 501-515
35. Beutler E., Gelbart T., and Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc Natl Acad Sci U S A 95 (1998) 8170-8174
36. de Jong F.A., Kehrer D.F., Mathijssen R.H., et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 11 (2006) 944-954
37. Innocenti F., Undevia S.D., Iyer L., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 (2004) 1382-1388
38. Paoluzzi L., Singh A.S., Price D.K., et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44 (2004) 854-860
39. Toffoli G., Cecchin E., Corona G., et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24 (2006) 3061-3068
40. Monaghan G., Ryan M., Seddon R., et al. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347 (1996) 578-581
41. Kweekel DM, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 8 A.D.; E-pub ahead of print.
42. Ando Y., Saka H., Ando M., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60 (2000) 6921-6926
43. Marcuello E., Altes A., Menoyo A., et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91 (2004) 678-682
44. Kweekel D.M., Gelderblom H., Van der S.T., et al. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 99 (2008) 275-282
45. Han J.Y., Lim H.S., Shin E.S., et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24 (2006) 2237-2244
46. Innocenti F., Liu W., Chen P., et al. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 15 (2005) 295-301
47. Ando Y., Saka H., Asai G., et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9 (1998) 845-847
48. Gagne J.F., Montminy V., Belanger P., et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62 (2002) 608-617
49. Kweekel D.M., Gelderblom H., and Guchelaar H.J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31 (2005) 90-105
50. Metzger R., Leichman C.G., Danenberg K.D., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 (1998) 309-316
51. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 (2001) 4298-4304
52. Park D.J., Stoehlmacher J., Zhang W., et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61 (2001) 8654-8658
53. Spitz M.R., Wu X., Wang Y., et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61 (2001) 1354-1357
54. Lunn R.M., Helzlsouer K.J., Parshad R., et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21 (2000) 551-555
55. Liu B., Wei J., Zou Z., et al. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15 (2007) 1049-1053
56. Braun M.S., Richman S.D., Quirke P., et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26 (2008) 2690-2698
57. Monzo M., Moreno I., Navarro A., et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology 72 (2007) 364-370
58. Yu J.J., Mu C., Lee K.B., et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 382 (1997) 13-20
59. Viguier J., Boige V., Miquel C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11 (2005) 6212-6217
60. Martinez-Balibrea E., Abad A., Aranda E., et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 44 (2008) 1229-1237
61. Stoehlmacher J., Park D.J., Zhang W., et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91 (2004) 344-354
62. Monaco R., Rosal R., Dolan M.A., et al. Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J 26 (2007) 541-546
63. Gurubhagavatula S., Liu G., Park S., et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22 (2004) 2594-2601
64. Graziano F., Ruzzo A., Loupakis F., et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 26 (2008) 1427-1434
65. Frattini M., Saletti P., Romagnani E., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97 (2007) 1139-1145
66. Jhawer M., Goel S., Wilson A.J., et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68 (2008) 1953-1961
67. Zhang W., Gordon M., Press O.A., et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 16 (2006) 475-483
68. Pander J., Gelderblom H., and Guchelaar H.J. Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. Expert Opin Pharmacother 8 (2007) 1197-1210
69. Gebhardt F., Zanker K.S., and Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274 (1999) 13176-13180
70. Goncalves A., Esteyries S., Taylor-Smedra B., et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 8 (2008) 169
71. Nagashima F., Zhang W., Gordon M., et al. EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144). J Clin Oncol 25 18S (2007) 4129
72. Papafili A., Hill M.R., Brull D.J., et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22 (2002) 1631-1636
73. Koene H.R., Kleijer M., Algra J., et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90 (1997) 1109-1114
74. Dall'Ozzo S., Tartas S., Paintaud G., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64 (2004) 4664-4669
75. Musolino A., Naldi N., Bortesi B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26 (2008) 1789-1796
76. Zhang W., Gordon M., Schultheis A.M., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25 (2007) 3712-3718
77. Wildiers H., Guetens G., De B.G., et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88 (2003) 1979-1986
78. Shahbazi M., Fryer A.A., Pravica V., et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13 (2002) 260-264
79. Yang B., Cross D.F., Ollerenshaw M., et al. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 17 (2003) 1-6
80. Pander J., Gelderblom H., and Guchelaar H.J. Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today 12 (2007) 1054-1060
81. Koukourakis M.I., Papazoglou D., Giatromanolaki A., et al. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46 (2004) 293-298
82. Krippl P., Langsenlehner U., Renner W., et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106 (2003) 468-471
83. Lambrechts D., Storkebaum E., Morimoto M., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34 (2003) 383-394
84. Renner W., Kotschan S., Hoffmann C., et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37 (2000) 443-448
85. Awata T., Inoue K., Kurihara S., et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51 (2002) 1635-1639
86. Watson C.J., Webb N.J., Bottomley M.J., et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12 (2000) 1232-1235
87. Kim J.G., Sohn S.K., Chae Y.S., et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 18 (2007) 1030-1036
88. Nikiteas N.I., Tzanakis N., Theodoropoulos G., et al. Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer 10 (2007) 12-17
89. Yamamori M., Sakaeda T., Nakamura T., et al. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun 325 (2004) 144-150
90. Schneider B.P., Wang M., Radovich M., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26 (2008) 4672-4678
91. Jin Q., Hemminki K., Enquist K., et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11 (2005) 3647-3653
92. Lu H., Shu X.O., Cui Y., et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 65 (2005) 5015-5019
93. Yamamori M., Taniguchi M., Maeda S., et al. VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese. Int J Med Sci 5 (2008) 80-86
94. Lurje G., Zhang W., Schultheis A.M., et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 19 10 (2008) 1734-1741
95. Kawai Y., Sakano S., Korenaga Y., et al. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 52 (2007) 1147-1155
96. Koukourakis M.I., Papazoglou D., Giatromanolaki A., et al. C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1alpha gene define HIF-1alpha protein expression in non-small cell lung cancer. Lung Cancer 53 (2006) 257-262
97. Tanimoto K., Yoshiga K., Eguchi H., et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24 (2003) 1779-1783
98. Fu X.S., Choi E., Bubley G.J., et al. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 63 (2005) 215-221
99. Fransen K., Fenech M., Fredrikson M., et al. Association between ulcerative growth and hypoxia inducible factor-1alpha polymorphisms in colorectal cancer patients. Mol Carcinog 45 (2006) 833-840
100. Nadaoka J., Horikawa Y., Saito M., et al. Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer 122 (2008) 1297-1302
101. Gao R., Price D.K., Sissung T., et al. Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther 7 (2008) 1246-1250
102. Luo H.R., Lu X.M., Yao Y.G., et al. Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem Genet 40 (2002) 41-51
103. Morganti M., Ciantelli M., Giglioni B., et al. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41 (2005) 2176-2183
104. Wang W.S., Chen P.M., Chiou T.J., et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res 13 (2007) 3597-3604
105. Le Marchand L., Seifried A., Lum-Jones A., et al. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 290 (2003) 2843-2848
106. Wessels J.A., van der Kooij S.M., le C.S., et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56 (2007) 1765-1775
107. Minami H., Sai K., Saeki M., et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17 7 (2007 Jul) 497-504
108. Quintela-Fandino M., Hitt R., Medina P.P., et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24 26 (2006 Sep 10) 4333-4339
109. Sakano S., Wada T., Matsumoto H., et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 95 5 (2006 Sep 4) 561-570